![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Author: Ku Geoffrey Y Ilson David H
Publisher: Informa Healthcare
ISSN: 1472-8214
Source: Expert Opinion on Emerging Drugs, Vol.18, Iss.2, 2013-06, pp. : 219-230
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Related content
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Protein tyrosine kinase inhibitors in cancer treatment
By Traxler P.M.
Expert Opinion on Therapeutic Patents, Vol. 7, Iss. 6, 1997-06 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Tyrosine kinase inhibitors in cancer treatment (Part II)
By Traxler P.
Expert Opinion on Therapeutic Patents, Vol. 8, Iss. 12, 1998-12 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Novel Tyrosine Kinase Inhibitors in the Treatment of Cancer
Current Drug Targets, Vol. 10, Iss. 6, 2009-06 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Selective tyrosine kinase inhibitors
Expert Opinion on Emerging Drugs, Vol. 5, Iss. 3, 2000-10 ,pp. :